文献速递临床试验与 GCP流行病学与生物统计

住院注射吸毒者丙型肝炎机会性治疗:阶梯楔形整群随机试验方案

Opportunistic treatment of hepatitis C virus infection (OPPORTUNI-C): study protocol for a pragmatic stepped wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs.
PubMed 文献 · Trials · 2020-06-15

OPPORTUNI-C 是一项务实性阶梯楔形整群随机试验,在挪威三家医院住院的注射吸毒者中比较立即启动丙型肝炎治疗与常规出院后转诊的门诊治疗。主要结局为入组后6个月内从药房领取最终处方DAA药物包的治疗完成率,计划纳入约220例HCV RNA阳性者。

要点

  • 住院期立即评估肝病并启动泛基因型DAA治疗,替代出院后转诊模式。
  • 主要结局为入组后6个月内完成治疗(领取最终DAA药物包)。
  • 采用务实性设计、宽纳入标准与电子病历数据采集。

核心结论

  • 该研究将评估住院期立即启动DAA治疗能否提高注射吸毒者的HCV治疗完成率,为消除丙肝提供新护理模式证据。

研究设计与样本

  • 务实性阶梯楔形整群随机试验,7个集群在16个月内按阶梯方式从常规护理随机转入干预。
  • 随机化按集群规模分层,以分隔高流行集群。
  • 计划纳入约220例HCV RNA阳性住院者,来自挪威三家医院的内科、成瘾医学科和精神科。
  • 排除无法或不愿签署知情同意者,以及正在评估或治疗HCV者。

关键数值与推荐

  • 干预包括立即无创肝病评估、咨询和启动泛基因型DAA治疗,并个体化随访。
  • 常规护理为出院时转诊至门诊治疗。
  • 主要结局为入组后6个月内从药房领取最终处方DAA药物包。
  • 次要结局包括治疗 uptake、病毒学应答、再感染发生率和耐药相关替代。

临床怎么用

  • 若该模式被证实有效可行,可考虑替代当前标准护理并推广,以覆盖边缘化注射吸毒者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Scaled-up direct-acting antiviral (DAA) treatment of hepatitis C virus (HCV) infection among people who inject drugs (PWID) is crucial to reach the World Health Organization HCV elimination targets within 2030. One of the critical obstacles to HCV care in this population is the lack of treatment models within specialist healthcare adapted to marginalized individuals. METHODS: OPPORTUNI-C is a pragmatic stepped wedge cluster randomized trial comparing the efficacy of immediate initiation of HCV treatment with the current standard of care among PWID admitted for inpatient care. Screening for HCV RNA will be performed as soon as possible after admission. The intervention includes immediate non-invasive liver disease assessment, counseling, and initiation of pan-genotypic DAA treatment with individualized follow-up. Standard of care is a referral to outpatient care at discharge. To mimic usual clinical practice as closely as possible, we will use a pragmatic clinical trial approach utilizing clinical infrastructure, broad eligibility criteria, flexible intervention delivery, clinically relevant outcomes, and collection of data readily available from the electronic patient files. The stepped wedge design involves a sequential rollout of the intervention over 16 months, in which seven participating clusters will be randomized from standard of care to intervention in a stepwise manner. Randomization will be stratified according to cluster size to keep high prevalence clusters separated. The trial will include approximately 220 HCV RNA positive individuals recruited from departments of internal medicine, addiction medicine, and psychiatry at Akershus University Hospital, Oslo University Hospital, and Lovisenberg Diaconal Hospital, Oslo, Norway. Individuals not able or willing to give informed consent and those with ongoing HCV assessment or treatment will be excluded. The primary outcome is treatment completion, defined as dispensing of the final prescribed DAA package from the pharmacy within 6 months after inclusion. Secondary outcomes include treatment uptake, virologic response, reinfection incidence, and resistance-associated substitutions. DISCUSSION: Representing a novel model of care suited to reach and engage marginalized PWID in HCV care, this study will inform HCV elimination efforts locally and internationally. If the model proves efficacious and feasible, it should be considered for broader implementation, replacing the current standard of care. TRIAL REGISTRATION: ClinicalTrials.gov, NCT04220645. Registered on 7 January 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Midgard H, Finbråten AK, Malme KB, et al. Opportunistic treatment of hepatitis C virus infection (OPPORTUNI-C): study protocol for a pragmatic stepped wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs. Trials. 2020. PMID: 32539853. doi:10.1186/s13063-020-04434-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。